India, July 1 -- Jazz Pharmaceuticals plc (JAZZ) announced Tuesday that the European Commission (EC) has granted conditional marketing authorization for Ziihera (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.
BTCs, which include gallbladder cancer (GBC) and cholangiocarcinoma (CCA), are a rare and aggressive group of cancers, with most cases diagnosed at an advanced stage4 when curative surgery is no longer an option. Ziihera is the first HER2-targeted therapy given conditional aut...